Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice

Mutations underlying disease in tuberous sclerosis complex (TSC) give rise to tumors with biallelic mutations in TSC1 or TSC2 and hyperactive mammalian target of rapamycin complex 1 (mTORC1). Benign tumors might exhibit de novo expression of immunogens, targetable by immunotherapy. As tumors may rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Ancy, Sumughan, Saurav, Dellacecca, Emilia R., Shivde, Rohan S., Lancki, Nicola, Mukhatayev, Zhussipbek, Vaca, Cristina C., Han, Fei, Barse, Levi, Henning, Steven W., Zamora-Pineda, Jesus, Akhtar, Suhail, Gupta, Nikhilesh, Zahid, Jasmine O., Zack, Stephanie R., Ramesh, Prathyaya, Jaishankar, Dinesh, Lo, Agnes S.Y., Moss, Joel, Picken, Maria M., Darling, Thomas N., Scholtens, Denise M., Dilling, Daniel F., Junghans, Richard P., Le Poole, I. Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663788/
https://www.ncbi.nlm.nih.gov/pubmed/34806651
http://dx.doi.org/10.1172/jci.insight.152014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663788/
https://www.ncbi.nlm.nih.gov/pubmed/34806651
http://dx.doi.org/10.1172/jci.insight.152014

Ejemplares similares